Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01

Jinghua Piao, Susan Zabierowski, Brittany N. Dubose, Ellen J. Hill, Monalisa Navare, Nidia Claros, Siera Rosen, Kiran Ramnarine, Callie Horn, Craig Fredrickson, Karen Wong, Brent Safford, Sonja Kriks, Abderrahman El Maarouf, Urs Rutishauser, Claire Henchcliffe, Yongzeng Wang, Isabelle Riviere, Shannon Mann, Vladimir BermudezStefan Irion, Lorenz Studer, Mark Tomishima, Viviane Tabar

Research output: Contribution to journalArticlepeer-review

110 Scopus citations

Abstract

Tabar et al. report the development of an hESC-derived dopamine neuron product for clinical applications.

Original languageEnglish
Pages (from-to)217-229.e7
JournalCell Stem Cell
Volume28
Issue number2
DOIs
StatePublished - 4 Feb 2021
Externally publishedYes

Keywords

  • GMP
  • Parkinson's disease
  • cell therapy
  • dopamine neurons
  • human embryonic stem cells
  • human pluripotent stem cells
  • preclinical study
  • safety studies
  • transplantation

Fingerprint

Dive into the research topics of 'Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01'. Together they form a unique fingerprint.

Cite this